| Literature DB >> 28357087 |
Zihai Ding1, Zheng Wang2, Shijie Huang3, Shizhen Zhong1, Jianhua Lin4.
Abstract
This study was conducted to evaluate the safety of laparoscopic radical resection for rectal cancer. A total of 64 cases of rectal cancer patients undergoing radical surgery between January, 1998 and March, 2010 were collected. The patients were divided into the laparoscopic rectal surgery group (LS group, n=31) and the open surgery group (OS group, n=33). Operation time, postoperative recovery, complications and tumor-free survival rate were compared between the two groups. The inclusion criteria were as follows: Standard Karnofsky score >70 prior to surgery, definitive pathological diagnosis and complete clinical data. The exclusion criteria were concomitant tumors affecting survival. With the Dixon operation, the LS group had a longer operation time compared with the OS group (271.2±56.2 vs. 216.0±62.7 min, respectively; P=0.036), and an earlier time of oral intake (3.0±0.9 vs. 4.7±1.0 days, respectively; P=0.000). There were no significant differences between the LS and OS groups in terms of intraoperative blood loss, number of lymph nodes retrieved, duration of postoperative hyperthermia and hospitalization time (P>0.05). With the Miles operation, there were no obvious differences between the LS and OS groups regarding operation time, intraoperative blood loss, number of lymph nodes retrieved, time of oral intake, duration of postoperative hyperthermia and hospitalization time (P>0.05). Furthermore, there were no significant differences between the LS and OS groups with the Dixon or Miles operation in terms of 3-year tumor-free survival rate (P>0.05). Thus, laparoscopic surgery appears to be a safe and feasible option for the treatment of rectal cancer.Entities:
Keywords: laparoscopic; open surgery; radical resection; rectal cancer
Year: 2016 PMID: 28357087 PMCID: PMC5351748 DOI: 10.3892/mco.2016.1112
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450
Comparison of general clinical data between the LS and OS groups.
| Parameters | LS group (n=31) | OS group (n=33) | P-value |
|---|---|---|---|
| Age, years (mean ± SD) | 65.6±10.9 | 63.0±1.8 | 0.448 |
| Gender (male/female) | 18/13 | 19/14 | 0.968 |
| BMI, kg/m2 (mean ± SD) | 22.6±3.3 | 23.3±3.0 | 0.624 |
| Tumor location (distance from anus, cm) | 7.8±4.8 | 8.6±3.4 | 0.669 |
| TNM stage | 0.999 | ||
| 0 | 1 | 1 | |
| I | 14 | 15 | |
| II | 10 | 11 | |
| III | 6 | 6 | |
| pT stage | 0.921 | ||
| Tis | 2 | 1 | |
| T1 | 3 | 4 | |
| T2 | 10 | 11 | |
| T3 | 16 | 17 | |
| pN stage | 0.911 | ||
| N0 | 22 | 23 | |
| N1 | 9 | 10 | |
| Type of surgery | 1.000 | ||
| Anterior resection | 21 | 22 | |
| AP excision | 10 | 11 |
There was no significant difference between the LS and OS groups regarding general clinical data (P>0.05). LS, laparoscopic surgery; OS, open surgery; BMI, body mass index; SD, standard deviation; TNM, tumor-node-metastasis; AP, abdominoperineal.
Comparison of general clinical data between the LS and OS groups with the Dixon operation.
| Parameters | LS group (n=20) | OS group (n=21) | P-value |
|---|---|---|---|
| Age, years (mean ± SD) | 67.8±10.4 | 64.4±10.4 | 0.376 |
| Gender (male/female) | 15/5 | 15/6 | 0.796 |
| BMI, kg/m2 (mean ± SD) | 23.0±3.6 | 23.6±3.8 | 0.630 |
| Preoperative anemia | 0 | 1 | |
| Preoperative high CEA | 10 | 8 | 0.443 |
| Tumor location (distance from anus, cm, mean ± SD) | 12.3±2.5 | 8.9±3.3 | 0.116 |
| Tumor maximum diameter (cm, mean ± SD) | 4.7±1.2 | 4.0±1.5 | 0.225 |
| TNM stage | 0.698 | ||
| 0 | 1 | ||
| I | 8 | 9 | |
| II | 6 | 8 | |
| III | 5 | 4 | |
| pT stage | 0.997 | ||
| Tis | 1 | 1 | |
| T1 | 2 | 2 | |
| T2 | 6 | 7 | |
| T3 | 11 | 11 | |
| pN stage | 0.837 | ||
| N0 | 13 | 13 | |
| N1 | 7 | 8 | |
| Dukes' stage | 0.904 | ||
| A | 5 | 6 | |
| B | 8 | 9 | |
| C | 7 | 6 | |
| Postoperative adjuvant chemotherapy | 6 | 14 | 0.019 |
There was no significant difference between the LS and OS groups with the Dixon operation regarding general clinical data (P>0.05), apart from postoperative adjuvant chemotherapy (P<0.05). LS, laparoscopic surgery; OS, open surgery; BMI, body mass index; SD, standard deviation; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.
Comparison of general clinical data between the LS and OS groups with the Miles operation.
| Parameters | LS group (n=11) | OS group (n=12) | P-value |
|---|---|---|---|
| Age, years (mean ± SD) | 62.2±11.6 | 57.5±16.6 | 0.555 |
| Gender (male/female) | 3/8 | 4/8 | 0.752 |
| BMI, kg/m2 (mean ± SD) | 22.9±3.0 | 23.0±2.8 | 0.619 |
| Preoperative anemia | 2 | 4 | |
| Preoperative high CEA | 8 | 6 | 0.265 |
| Tumor location (distance from anus, cm; mean ± SD) | 4.4±2.4 | 4.0±1.0 | 0.814 |
| Tumor maximum diameter, cm (mean ± SD) | 4.5±1.7 | 5.1±2.6 | 0.557 |
| TNM stage | 0.697 | ||
| 0 | 1 | ||
| I | 6 | 6 | |
| II | 4 | 3 | |
| III | 1 | 2 | |
| pT stage | 0.709 | ||
| Tis | 1 | 0 | |
| T1 | 1 | 2 | |
| T2 | 4 | 4 | |
| T3 | 5 | 6 | |
| pN stage | 0.924 | ||
| N0 | 9 | 10 | |
| N1 | 2 | 2 | |
| Dukes' stage | 0.925 | ||
| A | 5 | 5 | |
| B | 4 | 4 | |
| C | 2 | 3 | |
| Postoperative adjuvant chemotherapy | 6 | 10 | 0.134 |
There was no significant difference between the LS and OS groups with the Miles operation regarding general clinical data (P>0.05). LS, laparoscopic surgery; OS, open surgery; BMI, body mass index; SD, standard deviation; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.
Comparison of therapeutic effect between the LS group and OS groups with the Dixon operation.
| Parameters | LS group (n=20) | OS group (n=21) | P-value |
|---|---|---|---|
| Operation time, min (mean ± SD) | 271.2±56.2 | 216.0±62.7 | 0.036 |
| Intraoperative blood loss, ml (mean ± SD) | 107.1±69.4 | 166.4±81.6 | 0.096 |
| Number of lymph nodes retrieved (mean ± SD) | 7±4 | 6±6 | 0.604 |
| Time to oral intake, days (mean ± SD) | 3.0±0.9 | 4.7±1.0 | 0.000 |
| Duration of postoperative hyperthermia, days (mean ± SD) | 2.6±0.5 | 2.6±1.6 | 0.930 |
| Postoperative complications | |||
| Pulmonary infection | 0 | 1 | |
| Intestinal adhesion | 0 | 1 | |
| Fistula | 1 | 0 | |
| Hospitalization, days (mean ± SD) | 19.8±3.8 | 25.8±5.2 | 0.067 |
| 3-year tumor-free survival rate (%) | 35.0 | 38.1 | 0.837 |
| Postoperative recurrence/metastasis | |||
| Local recurrence | 1 | 1 | |
| Pulmonary metastasis | 0 | 1 | |
| Multiple metastasis | 0 | 1 |
There was no significant difference between the LS and OS groups with the Dixon operation regarding therapeutic effect (P>0.05), apart from operation time and time to oral intake (P<0.05). LS, laparoscopic surgery; OS, open surgery; SD, standard deviation.
Comparison of therapeutic effect between the LS and OS groups with the Miles operation.
| Parameters | LS group (n=11) | OS group (n=12) | P-value |
|---|---|---|---|
| Operative time, min (mean ± SD) | 310.5±93.2 | 284.2±77.2 | 0.551 |
| Intraoperative blood loss, ml (mean ± SD) | 211.1±74.0 | 280.0±164.3 | 0.416 |
| Number of lymph nodes retrieved (mean ± SD) | 5±7 | 8±4 | 0.429 |
| Time to oral intake, days (mean ± SD) | 3.1±0.4 | 3.7±1.0 | 0.203 |
| Duration of postoperative hyperthermia, days (mean ± SD) | 2.4±1.2 | 3.2±1.0 | 0.210 |
| Postoperative complications | |||
| Pulmonary infection | 1 | 1 | |
| Intestinal adhesion | 0 | 1 | |
| Fistula | 0 | 0 | |
| Hospitalization time, days (mean ± SD) | 26.6±7.8 | 31.5±10.0 | 0.314 |
| 3-year tumor-free survival rate, % | 36.4 | 33.3 | 0.879 |
| Postoperative recurrence/metastasis | |||
| Local recurrence | 0 | 0 | |
| Pulmonary metastasis | 2 | 1 | |
| Multiple metastasis | 1 | 0 |
There was no significant difference between the LS and OS groups with the Miles operation regarding therapeutic effect (P>0.05). LS, laparoscopic surgery; OS, open surgery; SD, standard deviation.
Figure 1.Survival curves of the LS and OS groups with the Dixon operation. LS, laparoscopic surgery; OS, open surgery.
Figure 2.Survival curves of the LS and OS groups with the Miles operation. LS, laparoscopic surgery; OS, open surgery.